Interference with HIV infection of the first cell is essential for viral clearance at sub-optimal levels of drug inhibition.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
02 2020
Historique:
received: 14 02 2019
accepted: 10 10 2019
revised: 24 02 2020
pubmed: 6 2 2020
medline: 28 5 2020
entrez: 5 2 2020
Statut: epublish

Résumé

HIV infection can be cleared with antiretroviral drugs if they are administered before exposure, where exposure occurs at low viral doses which infect one or few cells. However, infection clearance does not happen once infection is established, and this may be because of the very early formation of a reservoir of latently infected cells. Here we investigated whether initial low dose infection could be cleared with sub-optimal drug inhibition which allows ongoing viral replication, and hence does not require latency for viral persistence. We derived a model for infection clearance with inputs being drug effects on ongoing viral replication and initial number of infected cells. We experimentally tested the model by inhibiting low dose infection with the drug tenofovir, which interferes with initial infection, and atazanavir, which reduces the cellular virion burst size and hence inhibits replication only after initial infection. Drugs were used at concentrations which allowed infection to expand. Under these conditions, tenofovir dramatically increased clearance while atazanavir did not. Addition of latency to the model resulted in a minor decrease in clearance probability if the drug inhibited initial infection. If not, latency strongly decreased clearance even at low latent cell frequencies. Therefore, the ability of drugs to clear initial but not established infection can be recapitulated without latency and depends only on the ability to target initial infection. The presence of latency can dramatically decrease infection clearance, but only if the drug is unable to interfere with infection of the first cells.

Identifiants

pubmed: 32017770
doi: 10.1371/journal.pcbi.1007482
pii: PCOMPBIOL-D-19-00247
pmc: PMC7039526
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1007482

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI138546
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Cell Host Microbe. 2014 Dec 10;16(6):711-21
pubmed: 25467409
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S240-7
pubmed: 23764642
Cell. 2005 Jul 29;122(2):169-82
pubmed: 16051143
N Engl J Med. 2016 Dec;375(22):2121-2132
pubmed: 26900902
PLoS One. 2013;8(1):e53138
pubmed: 23308151
Nature. 1997 May 8;387(6629):183-8
pubmed: 9144289
Nature. 2011 Aug 17;477(7362):95-8
pubmed: 21849975
Nat Cell Biol. 2008 Feb;10(2):211-9
pubmed: 18193035
J Virol. 2009 Jun;83(12):6234-46
pubmed: 19369333
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
Trends Microbiol. 2015 May;23(5):289-95
pubmed: 25766144
N Engl J Med. 2015 Feb 5;372(6):509-18
pubmed: 25651245
J Clin Invest. 2013 Sep;123(9):3848-60
pubmed: 23979165
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7
pubmed: 9371822
Curr HIV Res. 2007 Jul;5(4):394-402
pubmed: 17627502
J Exp Med. 2004 Jan 19;199(2):283-93
pubmed: 14734528
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
Nat Med. 2016 Apr;22(4):362-8
pubmed: 26998834
PLoS Med. 2008 Feb;5(2):e28
pubmed: 18254653
J Virol. 2005 Jul;79(14):9217-27
pubmed: 15994816
Cell. 2015 Feb 26;160(5):990-1001
pubmed: 25723172
Cell Host Microbe. 2012 Aug 16;12(2):132-8
pubmed: 22901535
Cell. 2015 Feb 26;160(5):1002-1012
pubmed: 25723173
PLoS Pathog. 2016 Nov 3;12(11):e1005964
pubmed: 27812216
Science. 1999 Nov 12;286(5443):1353-7
pubmed: 10558989
Nat Rev Microbiol. 2016 Jan;14(1):55-60
pubmed: 26616417
J Virol. 2011 Jul;85(14):7169-76
pubmed: 21543479
Science. 2009 Mar 27;323(5922):1743-7
pubmed: 19325119
Nature. 2014 Aug 7;512(7512):74-7
pubmed: 25042999
Nat Med. 2008 Jul;14(7):762-6
pubmed: 18552857
Immunity. 2001 Oct;15(4):671-82
pubmed: 11672548
Elife. 2018 Mar 20;7:
pubmed: 29555018
Nat Med. 2009 Aug;15(8):893-900
pubmed: 19543283
PLoS One. 2018 Jan 2;13(1):e0189945
pubmed: 29293546
Nat Med. 2003 Jun;9(6):727-8
pubmed: 12754504
Cell Rep. 2018 Aug 21;24(8):2088-2100
pubmed: 30134170
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
Proc Natl Acad Sci U S A. 1989 Apr;86(7):2336-40
pubmed: 2494664
APMIS. 2003 Jul-Aug;111(7-8):698-714
pubmed: 12974773
N Engl J Med. 2016 Dec;375(22):2133-2143
pubmed: 27959766
Cell Rep. 2016 Jun 21;15(12):2771-83
pubmed: 27292632
Virology. 2013 Nov;446(1-2):283-92
pubmed: 24074592
Annu Rev Immunol. 2000;18:665-708
pubmed: 10837072
J Virol. 2014 Feb;88(4):2025-34
pubmed: 24307588
Cell. 2013 Oct 24;155(3):540-51
pubmed: 24243014
Science. 1996 Mar 15;271(5255):1582-6
pubmed: 8599114
J Virol. 2013 Apr;87(8):4716-27
pubmed: 23408629
Lancet. 2013 Jun 15;381(9883):2083-90
pubmed: 23769234
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
Nat Cell Biol. 2007 Mar;9(3):310-5
pubmed: 17293854
AIDS. 2010 Mar 27;24(6):907-13
pubmed: 20139750
Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19079-84
pubmed: 18025463
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
Nature. 2019 Feb;566(7742):120-125
pubmed: 30700913
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
pubmed: 18490657
Lancet. 2001 Apr 14;357(9263):1149-53
pubmed: 11323041
Nat Med. 1999 May;5(5):512-7
pubmed: 10229227
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
J Virol. 2010 Jun;84(12):6096-102
pubmed: 20357090
PLoS Pathog. 2012;8(4):e1002634
pubmed: 22496655
Annu Rev Med. 2011;62:127-39
pubmed: 21054171
PLoS Pathog. 2013 Feb;9(2):e1003174
pubmed: 23459007
Science. 2010 Sep 3;329(5996):1168-74
pubmed: 20643915
J Exp Med. 2009 Jun 8;206(6):1273-89
pubmed: 19487424
Cell Rep. 2017 Jan 24;18(4):1062-1074
pubmed: 28122231

Auteurs

Ana Moyano (A)

Africa Health Research Institute, KwaZulu-Natal, South Africa.
School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.

Gila Lustig (G)

Africa Health Research Institute, KwaZulu-Natal, South Africa.

Hylton E Rodel (HE)

Africa Health Research Institute, KwaZulu-Natal, South Africa.
School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.

Tibor Antal (T)

School of Mathematics, University of Edinburgh, Edinburgh, United Kingdom.

Alex Sigal (A)

Africa Health Research Institute, KwaZulu-Natal, South Africa.
School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
Max Planck Institute for Infection Biology, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH